Pilot Study To Assess Effect of Treatment and Adherence in PD Subjects
NCT01788696 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2015-06-12
Summary
The purpose of this study is to evaluate the impact of imaging the brain as a diagnostic tool in the management of early Parkinson's disease (PD).
Conditions
- Parkinson Disease
Interventions
- RADIATION
-
Group A - Early Imaging
Total of 3 scans
- RADIATION
-
Group B - Delayed Imaging
Total of 2 scans
Sponsors & Collaborators
-
GE Healthcare
collaborator INDUSTRY - lead OTHER
Principal Investigators
-
Patrick Hickey, DO · Duke University Health Center
Study Design
- Allocation
- RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-06-30
- Primary Completion
- 2015-03-31
- Completion
- 2015-06-30
Countries
- United States
Study Locations
More Related Trials
-
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)
NCT01227265 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
NCT04193527 ·Status: COMPLETED ·Phase: PHASE3
-
Study of IRX4204 for Treatment of Early Parkinson's Disease
NCT02438215 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease
NCT03295786 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
PF-06669571 In Subjects With Idiopathic Parkinson's Disease
NCT02565628 ·Status: COMPLETED ·Phase: PHASE1
-
Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease
NCT00623363 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.
NCT00970229 ·Status: COMPLETED ·Phase: PHASE1
-
PF 06412562 in Subjects With Advanced Stage Parkinson's Disease
NCT03665454 ·Status: COMPLETED ·Phase: PHASE1
-
A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)
NCT01155466 ·Status: COMPLETED ·Phase: PHASE3
-
SHARPEN - Parkinson's Disease Dementia
NCT05987540 ·Status: TERMINATED ·Phase: NA
-
A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664)
NCT01155479 ·Status: TERMINATED ·Phase: PHASE3
-
Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT
NCT00566462 ·Status: TERMINATED ·Phase: PHASE2
-
Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease
NCT00096720 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants
NCT02337738 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's Disease
NCT00220272 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate SYN115 in Parkinson's Disease
NCT00605553 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease
NCT00040404 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease
NCT07348250 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Observational Study for Non-motor Symptoms and Treatment in Parkinson's Disease Patients
NCT02073981 ·Status: COMPLETED
-
Comparison of the Incidence of Dyskinesia in Parkinson's Disease Who Were Treated With Amantadine or Dopamine Agonist
NCT01338662 ·Status: UNKNOWN
-
An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)
NCT01215227 ·Status: TERMINATED ·Phase: PHASE3
-
Study to Evaluate DNL151 in Subjects With Parkinson's Disease
NCT04056689 ·Status: COMPLETED ·Phase: PHASE1
-
The Stanford Parkinson's Disease Plasma Study
NCT02968433 ·Status: COMPLETED ·Phase: PHASE1
-
iDAP Injection in the Treatment of Parkinson's Disease
NCT06583291 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Cognitive Decline in Non-demented PD
NCT01340885 ·Status: COMPLETED ·Phase: PHASE4